Literature DB >> 25040504

Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.

Cristina Novembrino1, Alessio Aghemo, Chiara Ferraris Fusarini, Rita Maiavacca, Caterina Matinato, Giovanna Lunghi, Erminio Torresani, Mariangela Ronchi, Maria Cristina Garlaschi, Miriam Ramondetta, Massimo Colombo.   

Abstract

A cytoplasmic antigen associated to inosine-5'-monophosphatedehydrogenase 2 eliciting specific antibodies (antirods and rings, RR) has been identified in patients with chronic hepatitis C who were exposed to pegylated interferon (PI) and ribavirin (RBV). The significance of anti-RR in these patients merits to be investigated. Sera from 88 chronic hepatitis C virus (HCV)-infected patients undergoing PI-RBV therapy were analysed for the presence of RR pattern by indirect immunofluorescence on HEp-2 substrate (Inova Diagnostics, San Diego, CA, USA). Anti-RR antibodies developed de novo in 32 patients independently of any demographic and virological feature, but with a significant association with cumulative exposure to PI-RBV (P = 0.0089; chi-square test). RR pattern was significantly more frequent in relapsers than in patients achieving sustained virological response (56% vs 30%; P = 0.0282, chi-square test). Anti-RR titre ranged from 1:80 to 1:1280, but significantly declined following treatment cessation. Anti-RR develop de novo in a substantial proportion of patients exposed to PI-RBV in relation to the duration of treatment exposure. Further investigations are necessary to unravel the mechanisms leading to the formation of these autoantibodies.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoantibodies; hepatitis C virus; inosine-5'-monophosphatedehydrogenase 2; interferon; ribavirin

Mesh:

Substances:

Year:  2014        PMID: 25040504     DOI: 10.1111/jvh.12281

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors:  Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.

Authors:  Ana Beatriz da Silva Sacerdote; Norma Arteiro Filgueira; Silvana de Barros Barreto; Andréa Dória Batista; Edmundo Pessoa Lopes
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

3.  The value of anti-rods and rings antibodies in patients with nonhepatitis virus infection: A single-center retrospective study from Southwest China.

Authors:  Naidan Zhang; Chaixia Ji; Hao Yang; Lihong Liu; Xiao Bao; Yusha Zhou; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

4.  Anti-rods and rings autoantibodies in a patient with hepatitis C virus infection.

Authors:  Kyung Ho Choi; Young Ae Lim; Think You Kim; La He Jearn; Sae Yun Baik; Sung Won Cho; Eunju Jeong
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

5.  Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.

Authors:  S John Calise; Nicola Bizzaro; Thuy Nguyen; Danila Bassetti; Brunetta Porcelli; Paolo Almi; Giuseppina Barberio; Giampaola Pesce; Minoru Satoh; Edward K L Chan
Journal:  Auto Immun Highlights       Date:  2016-11-14

6.  Long-term antiviral hepatitis C treatment associated with Rods and Ring Cytoplasmic antibodies.

Authors:  Vasile Feldrihan; Andreea Benea; Monica Lia Junie
Journal:  Med Pharm Rep       Date:  2019-01-15

7.  Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.

Authors:  Jan Damoiseaux; Luis Eduardo Coelho Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia de la Torre; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Carlos von Muhlen; Minoru Satoh; Edward K Chan
Journal:  Ann Rheum Dis       Date:  2019-03-12       Impact factor: 19.103

8.  High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection.

Authors:  Geison Luiz Costa de Castro; Ednelza da Silva Graça Amoras; Mauro Sérgio Araújo; Simone Regina Souza da Silva Conde; Carlos David Araújo Bichara; Maria Alice Freitas Queiroz; Antonio Carlos Rosário Vallinoto
Journal:  Eur J Med Res       Date:  2022-09-16       Impact factor: 4.981

9.  The clinical value of indirect immunofluorescence for screening anti-rods and rings antibodies: A retrospective study of two centers in China.

Authors:  Jingjing Meng; Guoxiang Yang; Siting Li; Yueming Luo; Yina Bai; Chuiwen Deng; Ning Song; Mengtao Li; Xiaofeng Zeng; Chaojun Hu
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.